Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupAggressive LymphomasT-Cell and NK-Cell NeoplasmsDiseaseNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, IndolentNHL, T-Cell Type, Anaplastic Large CellSubgroupICD10C83.3C84.4MeSHLymphoma, T-CellSequenceChemotherapyChemo-substanceCisplatinDexamethasoneGemcitabineRituximabChemo-substanceCisplatinDexamethasoneGemcitabineRituximabChemo-substanceCisplatinDexamethasoneGemcitabineRituximabChemo-substanceCisplatinDexamethasoneGemcitabineRituximabNo. Substances4 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateParacetamolPegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateParacetamolPegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateParacetamolPegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateParacetamolPegfilgrastimPotassium chlorideNo. Substances10Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationSecond lineTherapy phaseTherapy intentioncurativeRisksEmetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaInfectionsThromboembolic EventVomiting only studiesPublicationAuthorCrump MDiseaseRezidivierte oder refraktäre, aggressive Lymphome, 2. Linie vor ASCT, ECOG 0-3OriginPrincess Margaret Cancer Centre, Ontario, CanadaProtocols in Revision 1 protocol foundProtocols under revision.R-GDP - Rituximab 375 / Gemcitabine 1000 / Dexamethasone 40 / Cisplatin 75, diffuse large B-non-Hodgkin Lymphoma (PID605 V1.4)
